Navigation Links
Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free protein synthesis technology towards commercialization.

During Small Business Technology Transfer (STTR) Phase I and Phase II NSF projects, FAB successfully demonstrated that certain proteins could be made in a cell-free system in a soluble form, in a controllable and efficient fashion. With the Phase IIb grant, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB's first target product.

"We are pleased to receive this grant from the NSF," said Daniel S. Gold, PhD, CEO of FAB. "The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity."

"This grant reflects NSF's continued interest in the commercialization potential of cell-free technology. The STTR Phase I and II grants were instrumental in supporting FAB's research initiatives to develop marketable biologics as a continuation of work initiated in my laboratory at the Department of Chemical Engineering at Stanford University," noted Professor James Swartz, D.Sc.

Intact organisms which have the limitation of having to maintain their own viability can have difficulty making toxic or difficult to fold proteins. Cell-free technology was designed to overcome these limitations.

About Fundamental Applied Biology

Fundamental Applied Biology (FAB), Inc. is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics. FAB's goal is to become the leader in the field of cell-free protein synthesis by developing its own and collaborative therapies that will provide improved clinical outcomes for patients.

Contact:

Patricia Sinatra

VP, Business Development and Commercial Strategy

Fundamental Applied Biology, Inc.

(650) 329-9374

psinatra@cellfree.com

http://www.cellfree.com


'/>"/>
SOURCE Fundamental Applied Biology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
2. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
3. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
4. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
9. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
(Date:4/27/2016)... , April 27, 2016 ... of the  "Global Anesthesia Disposables Market 2016-2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ,The global anesthesia disposables ... CAGR of 4.03% during the period 2016-2020.  ... major threat to patients, safety. Organizations like ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... 2016 , ... “Aging well is a challenge for all of us, but there are things we can do ... . “Research is showing more and more that there are simple, yet important steps that ... we age.” Top priorities Dr. Kohli’s recommends for her patients include;, , ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since ... the national charitable foundation serving the footwear industry, has broken all previous participation ... than 130 companies across 23 states during the months of April and May, ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce ... stability, even security. Most importantly, employees are the single most important asset in ... workers so unhappy? , Just under half of American workers are emotionally checked ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
Breaking Medicine News(10 mins):